IRLAB says WHO assigns generic name linepemat to Parkinson’s apathy drug candidate in Phase Ib trial

PUBT · 2d ago
IRLAB says WHO assigns generic name linepemat to Parkinson’s apathy drug candidate in Phase Ib trial
  • IRLAB Therapeutics announced WHO assigned IRL757 the generic name linepemat, supporting its positioning as a distinct drug candidate.
  • Linepemat is being evaluated in the Phase Ib LIFT-PD study for apathy linked to Parkinson’s disease, an area with no approved drug treatments.
  • Clinical results have not been presented; first LIFT-PD readout is scheduled for mid-2027.
  • The program remains under IRLAB’s ownership; Otsuka is funding the trial, with an option to broaden the collaboration later.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRLAB Therapeutics AB published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein.